What does an overnight dexamethasone (DST) suppression test with a cortisol level of 1.1 and a dexamethasone level of 426 indicate in a patient being evaluated for Cushing's syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Interpretation of Dexamethasone Suppression Test Results

This result indicates normal cortisol suppression and effectively rules out Cushing's syndrome. The cortisol level of 1.1 μg/dL is well below the diagnostic threshold of 1.8 μg/dL, and the dexamethasone level of 426 ng/mL confirms adequate drug absorption and test validity 1, 2.

Understanding the Test Results

Your patient has demonstrated intact hypothalamic-pituitary-adrenal axis function with appropriate negative feedback. The cortisol value of 1.1 μg/dL after overnight dexamethasone suppression is substantially below the normal cutoff of <1.8 μg/dL (50 nmol/L), indicating proper suppression 1, 2, 3.

Dexamethasone Level Significance

The dexamethasone level of 426 ng/mL is critical for interpreting this result:

  • This elevated dexamethasone level confirms the test's validity by demonstrating adequate drug absorption and ruling out false-negative results from rapid metabolism or malabsorption 1, 2, 3
  • The lower limit of normal for dexamethasone is 1.8 ng/mL (4.6 nmol/L), so a level of 426 ng/mL far exceeds this threshold 3
  • Measuring dexamethasone concomitantly with cortisol reduces false-positive DST results and is considered best practice 1, 2

Clinical Implications

No further biochemical testing for hypercortisolism is indicated based on this result. The combination of suppressed cortisol and adequate dexamethasone levels provides high confidence in excluding autonomous cortisol secretion 1, 3.

Specific Next Steps

  • If this test was performed for adrenal incidentaloma workup, the mass can be classified as non-functioning from a cortisol perspective 1
  • If evaluating for Cushing's syndrome, this result excludes the diagnosis with high confidence 1, 3
  • No additional screening tests (24-hour urinary free cortisol, late-night salivary cortisol) are needed unless clinical suspicion remains extremely high for cyclic Cushing's syndrome 1, 2

Critical Pitfalls to Avoid

When to Reconsider Testing

Only pursue additional evaluation if:

  • Clinical features of Cushing's syndrome are severe and progressive despite this normal result 2
  • There is strong suspicion for cyclic Cushing's syndrome, which can produce weeks to months of normal cortisol secretion interspersed with hypercortisolism 1, 2
  • In cyclic disease, repeat testing during symptomatic periods over 3-6 months may be warranted 2

Understanding Test Limitations

While guidelines recommend a cutoff of 1.8 μg/dL, research demonstrates that some patients with mild or episodic Cushing's syndrome can suppress below this threshold 4, 5. However, with a cortisol of 1.1 μg/dL and confirmed adequate dexamethasone levels, the likelihood of missed disease is extremely low 1, 3.

The high dexamethasone level in your patient eliminates concerns about false-negative results from CYP3A4 inducers (phenobarbital, carbamazepine, St. John's wort) that accelerate dexamethasone metabolism 2, 3.

Documentation and Follow-Up

Document that the patient has:

  • Normal cortisol suppression (1.1 μg/dL, well below 1.8 μg/dL threshold) 1, 2
  • Adequate dexamethasone absorption confirmed (426 ng/mL) 1, 3
  • Intact HPA axis negative feedback 3
  • No evidence of autonomous cortisol secretion 1

If the patient has an adrenal incidentaloma, proceed with evaluation for pheochromocytoma and primary aldosteronism as clinically indicated, but cortisol excess is excluded 3.

References

Guideline

Cortisol Levels and Diagnostic Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Dexamethasone Suppression Test Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnosing Cushing's Syndrome with Dexamethasone Suppression Test

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

An update on the overnight dexamethasone suppression test for the diagnosis of Cushing's syndrome: limitations in patients with mild and/or episodic hypercortisolism.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006

Research

The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome.

The Journal of clinical endocrinology and metabolism, 2004

Related Questions

What is the workup for a patient with suspected increased mineralocorticoid (mineralocorticoid) precursors and an abnormal overnight 1 milligram (mg) dexamethasone (dexamethasone) suppression test?
What is the role of a dexamethasone (dex) suppression test in the workup for Cushing's syndrome?
What is the role of the cortisol with dexamethasone (DEX) suppression test in diagnosing and managing Cushing's syndrome in an adult patient?
How to confirm Cushing's syndrome if the low-dose Dexamethasone (corticosteroid) suppression test is positive?
What is the difference between checking morning (am) cortisol levels and a dexamethasone suppression test for diagnosing Cushing's syndrome?
Is a learning style that involves learning quickly by watching and mimicking (visual learning) a recognized and effective method of learning and cognitive development?
What is the recommended antibiotic treatment for an adult patient with an infected cyst?
What blood work is recommended for a female patient undergoing fertility testing?
What is the primary treatment goal and management plan for a patient with left ventricle diastolic function restrictive physiology, likely with underlying conditions such as hypertension, diabetes, or coronary artery disease?
What could be causing a female patient with a history of hyperparathyroidism, thrombocytosis, and elevated vitamin B12 levels, who discontinued progesterone and testosterone therapy, and is currently taking sermorelin (growth hormone-releasing hormone (GHRH) analogue) and tirzepatide (glucagon-like peptide-1 (GLP-1) receptor agonist), to experience delayed menstruation?
What is the best treatment approach for a patient with postnasal drip, considering their medical history and potential allergies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.